Outcome of patients with stage III or inoperable WT treated on the second United Kingdom WT protocol (UKWT2); a United Kingdom Children's Cancer Study Group (UKCCSG) study.
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D003609:Dactinomycin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D018714:Radiotherapy, Adjuvant; D018227:Sarcoma, Clear Cell / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D016019:Survival Analysis; D016896:Treatment Outcome; D006113:United Kingdom; D014750:Vincristine / Q000627:therapeutic use; D009396:Wilms Tumor / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy
D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin